Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
J Hans DeVries, Stephen C Bain, Helena W Rodbard, Jochen Seufert, David D'Alessio, Anne B Thomsen, Marcin Zychma, Julio Rosenstock, Liraglutide-Detemir Study Group, C Mathieu, C Vercammen, I Blumer, K Bowering, D B Clayton, J Conway, I Gottesman, S Harris, V Woo, C Allesis, S Angeletti, A Avignon, F Ayon, M Benichou, C Boitard, B Catargi, G Charpentier, S Clavel, J P Courreges, X Debussche, B Delemer, P Fontaine, E Ghanassia, D Gouet, E Haddad, S Hadjadj, P Hassler, I Hochner, N Le Moullec, P Lecomte, R Mira, P Moulin, D Reynaud, P Vexiau, A Barakat, T Behnke, D Burchert, R Daikeler, M Dietlein, K Drynda, E M Fach, S Goelz, A Hamann, H Hammer, M Hanefeld, A Hinz, R Jordan, M Kaiser, A Klinge, W Kohn, R Lundershausen, S Maxeiner, F Merfort, K Milek, A Mölle, B Paschen, A Pohl, L Rose, J Sauter, K Schlecht, C Schramm, P M Schumm-Draeger, J Schwinn, A Segner, J Seufert, E Siegel, J Simon, J Steindorf, P Stübler, R Tosch-Sisting, S Vidal, M Weber, V Wenzl-Bauer, K Wilhelm, A Arcangeli, M G Baroni, M Boemi, M Bonomo, A Bossi, S Buscemi, S Caputo, A Ciavarella, L Corsi, E Dal Moro, E D'Amico, P Di Bartolo, G Fatati, S Gambardella, L Morviducci, E Orsi, F Paleari, M Parillo, G Pipicelli, L Puccio, M Pupillo, A Sforza, F Tomasi, A Venezia, G Vespasiani, D Zavaroni, I Agous, A B Arntzenius, R Bianchi, C B Brouwer, H W De Valk, J H DeVries, W L Feis, G A P M Hentenaar, K Hoogenberg, M C W Jebbink, S Kok, A Kooy, B Lokhorst, H G M Mevissen, P C Oldenburg-Ligtenberg, D Schweitzer, V E K M Van de Walle, G J M van Doesburg, A H Verhage, M G J Willink, R Albero Gamboa, F J Ampudia-Blasco, J Anglada Barcelo, M Brito Sanfiel, F Cañizo, R Domínguez, J Dominguez Escribano, J Escalada, E Faure Nogueras, J Gómez Cerezo, E González Sarmiento, J Izaguirre, E Jodar, I Llorente Gómez De Segura, C López Tinoco, A Lucas, A Merchante Alfaro, P Mezquita Raya, F Morales Pérez, T Muros de Fuentes, M Paja Fano, J A Paniagua González, E Pujol De La Llave, L Ramírez Muñoz, W Ricart, A Rovira, A Sánchez Rodríguez, J M Varela Aguilar, P Abraham, J Andrews, S Atkin, S Bain, M Davies, C Dayan, M Gibson, R Harper, G Hitman, S Hunter, E Jude, A Kilvert, S Kumar, J Lindsay, A Mackie, S MacRury, D Matthews, J Mcknight, P Narendran, J O'Hare, S Ramtoola, A Robinson, D Rooney, D Russell-Jones, P Saravanan, W P Stephens, G Tan, B Vaidya, J Vora, D Whitelaw, J Wilding, P Wiles, P Winocour, F Abreu, M Acampora, A Ahmed, H Bays, R Bergenstal, O Brusco, L Chaykin, R Cherlin, S Chilka, M Christina, L Chuck, J Cohen, A Comulada-Rivera, C Corder, D D'Alessio, L Dunn, A Dwarakanathan, M Feinglos, R Forbes, J Gilbert, S Greco, G Griffing, M Harris, R Harris, S Harris, K Hershon, J Hoekstra, P Hollander, J Hone, D Huffman, R Jain, A Kapoor, D Kayne, J Kennedy, P Levin, R Lipetz, B Lubin, M McCartney, L Meneghini, A Murillo, F Ovalle, E Perez, L Phillips, D Popov, M Ramos-Roman, L Ratcliff, R Ratner, J Reed, H W Rodbard, J Rosenstock, R Sachson, J Saponaro, C Scott, J-L Selam, J Stoever, S Sulman, J Testa, A Philis-Tsimikas, J Unger, R Vigersky, P Weissman, K Wheeler, B Wittmer, G Yeoman, B Zamora, F Zieve, T Zimmerman, J Zonszein, J Hans DeVries, Stephen C Bain, Helena W Rodbard, Jochen Seufert, David D'Alessio, Anne B Thomsen, Marcin Zychma, Julio Rosenstock, Liraglutide-Detemir Study Group, C Mathieu, C Vercammen, I Blumer, K Bowering, D B Clayton, J Conway, I Gottesman, S Harris, V Woo, C Allesis, S Angeletti, A Avignon, F Ayon, M Benichou, C Boitard, B Catargi, G Charpentier, S Clavel, J P Courreges, X Debussche, B Delemer, P Fontaine, E Ghanassia, D Gouet, E Haddad, S Hadjadj, P Hassler, I Hochner, N Le Moullec, P Lecomte, R Mira, P Moulin, D Reynaud, P Vexiau, A Barakat, T Behnke, D Burchert, R Daikeler, M Dietlein, K Drynda, E M Fach, S Goelz, A Hamann, H Hammer, M Hanefeld, A Hinz, R Jordan, M Kaiser, A Klinge, W Kohn, R Lundershausen, S Maxeiner, F Merfort, K Milek, A Mölle, B Paschen, A Pohl, L Rose, J Sauter, K Schlecht, C Schramm, P M Schumm-Draeger, J Schwinn, A Segner, J Seufert, E Siegel, J Simon, J Steindorf, P Stübler, R Tosch-Sisting, S Vidal, M Weber, V Wenzl-Bauer, K Wilhelm, A Arcangeli, M G Baroni, M Boemi, M Bonomo, A Bossi, S Buscemi, S Caputo, A Ciavarella, L Corsi, E Dal Moro, E D'Amico, P Di Bartolo, G Fatati, S Gambardella, L Morviducci, E Orsi, F Paleari, M Parillo, G Pipicelli, L Puccio, M Pupillo, A Sforza, F Tomasi, A Venezia, G Vespasiani, D Zavaroni, I Agous, A B Arntzenius, R Bianchi, C B Brouwer, H W De Valk, J H DeVries, W L Feis, G A P M Hentenaar, K Hoogenberg, M C W Jebbink, S Kok, A Kooy, B Lokhorst, H G M Mevissen, P C Oldenburg-Ligtenberg, D Schweitzer, V E K M Van de Walle, G J M van Doesburg, A H Verhage, M G J Willink, R Albero Gamboa, F J Ampudia-Blasco, J Anglada Barcelo, M Brito Sanfiel, F Cañizo, R Domínguez, J Dominguez Escribano, J Escalada, E Faure Nogueras, J Gómez Cerezo, E González Sarmiento, J Izaguirre, E Jodar, I Llorente Gómez De Segura, C López Tinoco, A Lucas, A Merchante Alfaro, P Mezquita Raya, F Morales Pérez, T Muros de Fuentes, M Paja Fano, J A Paniagua González, E Pujol De La Llave, L Ramírez Muñoz, W Ricart, A Rovira, A Sánchez Rodríguez, J M Varela Aguilar, P Abraham, J Andrews, S Atkin, S Bain, M Davies, C Dayan, M Gibson, R Harper, G Hitman, S Hunter, E Jude, A Kilvert, S Kumar, J Lindsay, A Mackie, S MacRury, D Matthews, J Mcknight, P Narendran, J O'Hare, S Ramtoola, A Robinson, D Rooney, D Russell-Jones, P Saravanan, W P Stephens, G Tan, B Vaidya, J Vora, D Whitelaw, J Wilding, P Wiles, P Winocour, F Abreu, M Acampora, A Ahmed, H Bays, R Bergenstal, O Brusco, L Chaykin, R Cherlin, S Chilka, M Christina, L Chuck, J Cohen, A Comulada-Rivera, C Corder, D D'Alessio, L Dunn, A Dwarakanathan, M Feinglos, R Forbes, J Gilbert, S Greco, G Griffing, M Harris, R Harris, S Harris, K Hershon, J Hoekstra, P Hollander, J Hone, D Huffman, R Jain, A Kapoor, D Kayne, J Kennedy, P Levin, R Lipetz, B Lubin, M McCartney, L Meneghini, A Murillo, F Ovalle, E Perez, L Phillips, D Popov, M Ramos-Roman, L Ratcliff, R Ratner, J Reed, H W Rodbard, J Rosenstock, R Sachson, J Saponaro, C Scott, J-L Selam, J Stoever, S Sulman, J Testa, A Philis-Tsimikas, J Unger, R Vigersky, P Weissman, K Wheeler, B Wittmer, G Yeoman, B Zamora, F Zieve, T Zimmerman, J Zonszein
Abstract
Objective: We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%.
Research design and methods: In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups.
Results: Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change -1.3% from 7.7% at start), whereas 39% (n = 323) did not (-0.6% from 8.3% at start). During run-in, 167 of 988 (17%) withdrew; 46% of these due to gastrointestinal adverse events. At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference -0.52 [95% CI -0.68 to -0.36]; P < 0.0001). Forty-three percent of participants with insulin detemir versus 17% without reached A1C <7%. Mean weight decreased by 3.5 kg during run-in, then by 0.16 kg with insulin detemir or 0.95 kg without insulin detemir. In the randomized phase, no major hypoglycemia occurred and minor hypoglycemia rates were 0.286 and 0.029 events per participant-year with and without insulin detemir (9.2 vs. 1.3%).
Conclusions: Supplementation of metformin with liraglutide and then insulin detemir was well tolerated in the majority of patients, with good glycemic control, sustained weight loss, and very low hypoglycemia rates.
Trial registration: ClinicalTrials.gov NCT00856986.
Figures
References
- Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association. European Association for the Study of Diabetes Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17–30
- American Diabetes Association Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl. 1):S11–S61
- Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
- Nauck MA, Frid A, Hermansen K, et al. LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90
- Russell-Jones D, Vaag A, Schmitz O, et al. ; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial. Diabetologia 2009;52:2046–2055
- DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–1100
- Holman RR, Farmer AJ, Davies MJ, et al. 4-T Study Group Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736–1747
- Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073–1084
- International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice [Internet], 1996. Available from Accessed 9 August 2011
- World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects [Internet], 2008. Available from Accessed 9 August 2011
- Pratley RE, Nauck M, Bailey T, et al. 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447–1456
- Holman RR, Thorne KI, Farmer AJ, et al. 4-T Study Group Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–1730
- Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–1274
- Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569–1581
- Swinnen SG, Dain MP, Mauricio D, DeVries JH, Hoekstra JB, Holleman F. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes Obes Metab 2010;12:923–925
- Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 19 October 2011. [Epub ahead of print]
- Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834–838
- Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide—the FDA’s review of a new antidiabetic therapy. N Engl J Med 2010;362:774–777
- Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103–112
- Samarasinghe YP, Shlomowitz A, Munro N, Feher MD. The short term effects of exenatide therapy in insulin treated patients with type 2 diabetes mellitus–a new option to achieve weight loss (Abstract). Diabetologia 2008;51(Suppl. 1):S353
- Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008;14:285–292
- Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:444–450
- Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab 2009;11:623–631
- Zinman B, Gerich J, Buse JB, et al. LEAD-4 Study Investigators Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224–1230
- Nathan DM. Time for clinically relevant comparative effectiveness studies in type 2 diabetes. Ann Intern Med 2011;154:131–132
Source: PubMed